Cargando…

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies

SCY-078 is an orally bioavailable ß-1,3-glucan synthesis inhibitor (GSI) and the first-in-class of structurally novel triterpene antifungals in clinical development for treating candidemia and invasive candidiasis. In vitro susceptibilities by broth microdilution, antifungal carryover, and time-kill...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scorneaux, Bernard, Angulo, David, Borroto-Esoda, Katyna, Ghannoum, Mahmoud, Peel, Michael, Wring, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328566/ https://www.ncbi.nlm.nih.gov/pubmed/28069658 http://dx.doi.org/10.1128/AAC.01961-16

Ejemplares similares

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
por: Wring, Stephen A., et al.
Publicado: (2017)

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
por: Barat, Stephen, et al.
Publicado: (2017)

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
por: Larkin, Emily, et al.
Publicado: (2017)

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017)

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
por: Ghannoum, M., et al.
Publicado: (2018)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
por: Wring, Stephen, et al.
Publicado: (2018)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)
por: Huang, David, et al.
Publicado: (2021)

1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Huang, David, et al.
Publicado: (2021)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
por: Sobel, R, et al.
Publicado: (2021)

Natural Compounds: A Hopeful Promise as an Antibiofilm Agent Against Candida Species
por: Shariati, Aref, et al.
Publicado: (2022)

Combinatorial stresses kill pathogenic Candida species
por: Kaloriti, Despoina, et al.
Publicado: (2012)

Antifungal Mechanisms of a Chinese Herbal Medicine, Cao Huang Gui Xiang, Against Candida Species
por: Yue, Huizhen, et al.
Publicado: (2022)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
por: Feng, Joy Y, et al.
Publicado: (2009)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Corrigendum: Antifungal mechanisms of a Chinese herbal medicine, Cao Huang Gui Xiang, against Candida species
por: Yue, Huizhen, et al.
Publicado: (2022)

Identification of Fungicidal 2,6-Disubstituted Quinolines with Activity against Candida Biofilms
por: Delattin, Nicolas, et al.
Publicado: (2012)

CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms
por: Chandra, Jyotsna, et al.
Publicado: (2018)

Isoflavone formononetin from red propolis acts as a fungicide against Candida sp
por: das Neves, Michelline Viviane Marques, et al.
Publicado: (2016)

Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms
por: De Cremer, Kaat, et al.
Publicado: (2016)

In silico Prediction, Characterization, Molecular Docking, and Dynamic Studies on Fungal SDRs as Novel Targets for Searching Potential Fungicides Against Fusarium Wilt in Tomato
por: Aamir, Mohd, et al.
Publicado: (2018)

Eugenol: A novel therapeutic agent for the inhibition of Candida species infection
por: Didehdar, Mojtaba, et al.
Publicado: (2022)

In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans
por: Mahmoud, Dina Ezzat, et al.
Publicado: (2021)

Systemic Administration of Fibroblast Growth Factor 21 Improves the Recovery of Spinal Cord Injury (SCI) in Rats and Attenuates SCI-Induced Autophagy
por: Zhu, Sipin, et al.
Publicado: (2021)

In Vitro and In Vivo Anti-infective Potential of Thymol Against Early Childhood Caries Causing Dual Species Candida albicans and Streptococcus mutans
por: Priya, Arumugam, et al.
Publicado: (2021)

Antifungal activity of curcumin-silver nanoparticles against fluconazole-resistant clinical isolates of Candida species
por: Paul, Sony, et al.
Publicado: (2018)

Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans
por: Faria, Daniella Renata, et al.
Publicado: (2021)

Title unknown, CERN-ALEPH-2000-078
por: CERN. Geneva. ALEPH
Publicado: (2000)

Title unknown, CERN-ALEPH-97-078
por: CERN. Geneva. ALEPH
Publicado: (1997)

Appraisal of selected ethnomedicinal plants as alternative therapies against onychomycosis: Evaluation of synergy and time-kill kinetics
por: Mohsin, Syeda Aroosa, et al.
Publicado: (2022)

Expression of the Biologically Active Insulin Analog SCI-57 in Nicotiana Benthamiana
por: Muñoz-Talavera, Adriana, et al.
Publicado: (2019)

GM-CSF: Orchestrating the Pulmonary Response to Infection
por: McCormick, Thomas S., et al.
Publicado: (2022)

In Vitro and In Vivo Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection
por: Colley, Thomas, et al.
Publicado: (2018)

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
por: Larkin, Emily, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8sfg42eevsk2ojmne7brt0euu2